Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: Baseline and longitudinal data

International Journal of Cancer

Volumn 136, Issue 10, 2015, Pages 2361-2368

  Uijterwaal, Margot H ^a   Polman, Nicole J ^a   Witte, Birgit I ^a   Van Kemenade, Folkert J ^b   Rijkaart, Dorien ^a   Berkhof, Johannes ^a   Balfoort Van Der Meij, G A M A ^c   Ridder, Ruediger ^d   Snijders, Peter J F ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Saltro Diagnostic Centre   (Netherlands)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

cervical cytology; genotyping; human papillomavirus; p16 Ki 67 dual stained cytology

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; P16 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CELL STRUCTURE; CERVICAL BRUSH; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; GYNECOLOGICAL AND OBSTETRIC SAMPLING DEVICE; HUMAN; IMMUNOREACTIVITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOPATHOGENIC EFFECT; EARLY DIAGNOSIS; EMERGENCY HEALTH SERVICE; GENETICS; METABOLISM; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOPATHOGENIC EFFECT, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMANS; KI-67 ANTIGEN; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASM PROTEINS; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84924325756     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29290     Document Type: Article

References (27)

1. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-101.
2. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30: F88-99.
3. Standpunt minister van VWS screening op baarmoederhalskanker. Available from: www.rivm.nl/Documenten-en-publicaties/Algemeen-Actueel/Uitgaven/Preventie-Ziekte-Zorg/baarmoederhalskankerscreening/Standpunt-minister-van-VWS-screening-op-baarmoederhalskanker (accessed on January 31, 2014).
4. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
5. Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer. J Low Genit Tract Dis 2008; 12: 1-7.
6. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130: 602-10.
7. Dijkstra MG, van Niekerk D, Rijkaart DC, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev 2014; 23: 55-63.
8. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). Int J Cancer 2010; 126: 2175-81.
9. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011; 121: 505-9.
10. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013; 14: 168-76.
11. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105: 1550-7.
12. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012; 106: 975-81.
13. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJLM,. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57: 388-93.
14. Hanselaar AGJM,. Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol 2002; 46: 619-29.
15. van den Brule AJC, Pol R, Fransen-Daalmeijer N, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 779-87.
16. Hopman EH, Rozendaal L, Voorhorst FJ, et al. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG 2000; 107: 600-4.
17. Anderson MC,. Premalignant and malignant squamous lesions of the cervix. In:, Fox H, Wells M, Haines T, eds. Obstetrical and gynaecological pathology. New-York: Churchill Livingstone, 2013. 292-7.
18. Casparie M, Tiebosch ATMG, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007; 29: 19-24.
19. Bulkmans NWJ, Rozendaal L, Snijders PJF, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94-101.
20. Kocken M, Berkhof J, van Kemenade FJ, et al. Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing. Br J Cancer 2012; 106: 817-25.
21. Leisenring W, Alonzo T, Pepe MS,. Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics 2000; 56: 345-51.
22. R Development Core team. R: a language and environment for statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, www.R-project.org/. (Last accessed December 31, 2013).
23. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-6.
24. Denise ZG, Snijders PJ, Rozendaal L, et al. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol 2001; 195: 300-6.
25. Moseley RP, Paget S,. Liquid-based cytology: is this the way forward for cervical screening? Cytopathology 2002; 13: 71-82.
26. Choi BC,. Sensitivity and specificity of a single diagnostic test in the presence of work-up bias. J Clin Epidemiol 1992; 45: 581-6.
27. Ransohoff DF, Feinstein AR,. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299: 926-30.